Welcome to the Inaugural Next Generation Cancer Vaccine Development Summit
Cancer remains one of the most challenging diseases we face today. With standard treatment protocols consisting of chemotherapy, radiotherapy, and surgical intervention often being hampered by toxic side effects and concomitant malignancies, vaccines offer a promising alternative to unleash the most powerful force against cancer: our own immune system.
With a better understanding of which antigens to target, advances in combination therapies, and recent approvals of newer vaccine platforms, the re-emergence of cancer vaccines has been met with promising clinical data, renewed investments, and unprecedented industry partnerships.
The first Next Generation Cancer Vaccine Development Summit will focus on overcoming the translational and clinical challenges of developing cancer vaccines, including finding the right antigens, reassessing patient populations, understanding immune suppression and resistance patterns, and exploring case studies covering Ovarian Cancer, Pancreatic Cancer, Glioblastoma, Lung Cancer, Melanoma, Malignant pleural mesothelioma (MPM), Prostate Cancer, and Advanced Solid Tumors.
With a focus on mRNA, DNA, peptide, and other next-gen vaccines, this niche 3-day agenda has been specifically designed to help industry experts to:
Progress your own expertise and experience while forging complementary partnerships and alliances
Overcome immunogenicity challenges and design safe and efficacious vaccine formulations
Define clinically meaningful endpoints to successfully develop and safely deliver optimal doses for patient use
The digital Next Generation Cancer Vaccine Development Summit is not only the first, but the only dedicated meeting that brings you the most up to date clinical and commercial developments utilizing mRNA, DNA, peptide, and other next gen platforms to bring new cancer immunotherapies to market.